Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NISHANT GUPTA

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1487848875
CMS profile
1060543
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$109.56

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $109.56 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Biosense Webster, Inc. $109.56 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NISHANT GUPTA

NPI 1487848875 · CMS profile ID 1060543

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
NISHANT GUPTA, NPI 1487848875, CMS profile ID 1060543, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1487848875?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $109.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biosense Webster, Inc. $109.5601/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718878983 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $411.88 3
PY2020 $109.56 1
PY2021 $2.50 1
PY2022 $338.12 1
PY2023 $12,022.52 6
PY2025 $740.51 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $566,381.76 128
PY2024 Principal investigator $319,780.15 66
PY2023 Principal investigator $287,438.24 47
PY2022 Principal investigator $204,112.69 28
PY2021 Principal investigator $29,775.29 8
PY2020 Principal investigator $82,388.01 22
PY2019 Principal investigator $40,600.47 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 United Therapeutics Corporation $1,340.55 12/27/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199925
Principal investigator 1 United Therapeutics Corporation $3,732.90 12/27/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199927
Principal investigator 1 CSL Behring $717.30 12/13/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911759
Principal investigator 1 United Therapeutics Corporation $1,748.25 12/12/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199921
Principal investigator 1 United Therapeutics Corporation $4,665.60 12/12/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199923
Principal investigator 1 United Therapeutics Corporation $6,663.60 12/12/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199941
Principal investigator 1 CSL Behring $364.50 11/10/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911719
Principal investigator 1 United Therapeutics Corporation $3,078.00 11/07/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199939
Principal investigator 1 United Therapeutics Corporation $1,435.05 10/17/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199919
Principal investigator 1 CSL Behring $4,449.60 10/11/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911641
Principal investigator 1 CSL Behring $5,925.60 09/08/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911411
Principal investigator 1 United Therapeutics Corporation $1,435.05 09/06/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199911
Principal investigator 1 United Therapeutics Corporation $5,008.50 09/06/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199929
Principal investigator 1 CSL Behring $4,183.20 08/02/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911177
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $56,873.00 08/01/2023 Non-covered Recipient Entity
University of Cincinnati
PDE4 Phase III trial in PF ILD No dispute reported 06/30/2026 1022135721
Principal investigator 1 CSL Behring $69.95 08/01/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911965
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8.50 07/25/2023 Non-covered Recipient Entity
University Of Cincinnati
sGC activator in SSc patients No dispute reported 06/30/2026 1022141811
Principal investigator 1 United Therapeutics Corporation $7,308.90 07/25/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199915
Principal investigator 1 United Therapeutics Corporation $5,089.50 07/25/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199935
Principal investigator 1 United Therapeutics Corporation $2,099.25 07/25/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199937
Principal investigator 1 CSL Behring $12,200.40 07/19/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911155
Principal investigator 1 CSL Behring $349.75 07/12/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911947
Principal investigator 1 United Therapeutics Corporation $8,097.30 07/11/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199913
Principal investigator 1 United Therapeutics Corporation $625.00 07/11/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051199931
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,262.00 06/23/2023 Non-covered Recipient Entity
University of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1022138091
Principal investigator 1 United Therapeutics Corporation $7,710.00 06/21/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051198455
Principal investigator 1 United Therapeutics Corporation $4,955.85 06/21/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051198457
Principal investigator 1 Boehringer Ingelheim International GmbH $1,883.42 06/01/2023 Non-covered Recipient Entity
University Of Cincinnati
sGC activator in SSc patients No dispute reported 06/30/2026 1007649237
Principal investigator 1 Boehringer Ingelheim International GmbH $1,973.34 05/25/2023 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in PF ILD No dispute reported 06/30/2026 1007649229
Principal investigator 1 Roche Products Limited $4,748.40 05/25/2023 Non-covered Recipient Entity
UC Healthcare System
Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1040569575
Principal investigator 1 United Therapeutics Corporation $1,356.75 05/23/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051198467
Principal investigator 1 CSL Behring $209.85 05/22/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911907
Principal investigator 1 Roche Products Limited $28,570.00 05/18/2023 Non-covered Recipient Entity
University of Cincinnati
Ph III OLE Trial to Evaluate Long term Safety and Efficacy of PRM 151 in Patients with IPF No dispute reported 06/30/2026 1040581507
Principal investigator 1 CSL Behring $310.26 05/08/2023 Non-covered Recipient Entity
University of Cincinnati
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042911891
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $946.90 04/25/2023 Non-covered Recipient Entity
University Of Cincinnati
DCRI Registry Study No dispute reported 06/30/2026 1022141805
Principal investigator 1 Roche Products Limited $3,308.40 04/24/2023 Non-covered Recipient Entity
UC Healthcare System
Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1040569592
Principal investigator 1 United Therapeutics Corporation $15,500.00 04/18/2023 Non-covered Recipient Entity
University of Cincinnati
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051198453
Principal investigator 1 United Therapeutics Corporation $1,875.15 04/18/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051198465
Principal investigator 1 Roche Products Limited $7,600.00 03/21/2023 Non-covered Recipient Entity
UC Healthcare System
Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1040569543
Principal investigator 1 United Therapeutics Corporation $2,972.70 03/21/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051198463
Principal investigator 1 Roche Products Limited $2,226.00 03/13/2023 Non-covered Recipient Entity
UC Healthcare System
Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1040569525
Principal investigator 1 United Therapeutics Corporation $4,613.10 02/22/2023 Non-covered Recipient Entity
University of Cincinnati Physicians
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1051198461
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $14,632.08 02/02/2023 Non-covered Recipient Entity
University Of Cincinnati Medical Center-Division Of Pulmonary, Critical Care And Sleep Medicine
Phase II Pulmonary Fibrosis Add-On and Treatment Nave No dispute reported 06/30/2026 1027456957
Principal investigator 1 CSL Behring $209.85 02/01/2023 Non-covered Recipient Entity
Jadestone Clinical Research LLC
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of CSL312 in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1042913169
Principal investigator 1 Roche Products Limited $6,350.40 01/24/2023 Non-covered Recipient Entity
UC Healthcare System
Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients with Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1040569559
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,767.00 01/23/2023 Non-covered Recipient Entity
University Of Cincinnati
DCRI Registry Study No dispute reported 06/30/2026 1022141799
Principal investigator 1 Boehringer Ingelheim International GmbH $3,987.54 01/01/2023 Non-covered Recipient Entity
University Of Cincinnati
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1007644873